Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylactic neuroprotection.

Sean I Savitz1, Marc Fisher

  • 1Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. ssavitz@bidmc.harvard.edu

Current Drug Targets
|July 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Fibrinogen on Tenecteplase Treatment in Acute Ischaemic Stroke After 4.5 Hours of Symptom Onset: A Post Hoc Analysis of the TRACE-III Trial.

Neurology and therapy·2026
Same author

Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.

JAMA·2026
Same author

RNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known Well.

Stroke (Hoboken, N.J.)·2026
Same author

Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 h without thrombectomy-A secondary analysis of the TRACE-III randomized trial.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

Antithrombotic strategies for the secondary prevention of stroke: A review.

The American journal of medicine·2026
Same author

Cytoprotection Concepts for Ischemic Stroke in the Recanalization Era.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same journal

Extracellular Vesicles from Mesenchymal Stem Cells Alleviate Spinal Cord Injury via the miR-486-5p/PTEN/PI3K/AKT Pathway.

Current drug targets·2026
Same journal

Improving B-cell Linear Epitope Prediction <i>via</i> Multiple Feature Fusion and an Integrated Machine Learning Algorithm.

Current drug targets·2026
Same journal

Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis.

Current drug targets·2026
Same journal

Epitranscriptomics in Breast Cancer: The Unveiled Role of RNA Modifications.

Current drug targets·2026
Same journal

Neuroinflammation in Alzheimer's Disease: New Approaches.

Current drug targets·2026
Same journal

FXYD3: A Key Regulator of Ion Homeostasis and Redox Balance in Cancer Biology.

Current drug targets·2026
See all related articles

Prophylactic neuroprotection may reduce ischemic brain injury in high-risk patients. This review explores target populations and drug classes for future neuroprotection trials.

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Pharmacology

Background:

  • Ischemic brain injury is a risk in various clinical scenarios, including high-risk procedures, transient ischemic attacks, minor strokes, and multiple vascular risk factors.
  • Early recurrence and long-term stroke risk are significant concerns for these patient groups.
  • Prophylactic neuroprotection offers a potential strategy to mitigate ischemic events.

Purpose of the Study:

  • To identify optimal target populations for prophylactic neuroprotection trials.
  • To explore potential neuroprotective drug classes for these populations.
  • To guide future research in preventative neuroprotection strategies.

Main Methods:

  • Literature review focusing on clinical settings with high ischemic stroke risk.

Related Experiment Videos

  • Analysis of patient populations susceptible to ischemic brain injury.
  • Evaluation of existing and potential neuroprotective agents.

    • Main Results:

    • Specific patient groups identified as candidates for prophylactic neuroprotection include those undergoing high-risk procedures, experiencing recent transient ischemic attacks or minor strokes, and individuals with multiple vascular risk factors.
    • Various neuroprotective drug classes show promise, with selection dependent on the target population and desired duration of protection.
    • The review synthesizes current knowledge to inform the design of future clinical trials.

    Conclusions:

    • Prophylactic neuroprotection is a viable concept for reducing the impact of ischemic brain injury in carefully selected high-risk populations.
    • Further research and clinical trials are warranted to establish the efficacy and safety of specific neuroprotective strategies.
    • Tailoring neuroprotection approaches to distinct patient profiles is crucial for maximizing therapeutic benefit.